Daklinza Approval History
Marketing Status: Discontinued
Daklinza (daclatasvir) is an NS5A inhibitor indicated for use in combination with sofosbuvir for the treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection.
Development History and FDA Approval Process for Daklinza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.